Related Experiment Video
Updated: Oct 10, 2026
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
Effect of antiangiogenic agents on experimental animal models of hepatocellular carcinoma
1Liver Cancer Institute, Zhongshan Hospital, Shanghai Medical University, PR China.
Abstract:
A new therapeutic strategy for treating metastasis in hepatocellular carcinoma (HCC) has entailed the use of antiangiogenic agents such as suramin, BB-94 (Batimastat), TNP-470, and carboxyamido-triazole (CAI, a synthetic inhibitor of non-excitable calcium channels that reversibly inhibits angiogenesis). These agents have been used to treat metastatic model of HCC in nude mouse (LCI-D20 mouse model). The results of these studies are summarized in this paper with emphasis on the inhibitory effects of the drugs on tumour growth, angiogenesis, invasion and metastasis in LCI-D20 mouse models. The results suggest that all of the agents used can significantly inhibit tumour growth, angiogenesis, invasion and metastasis of human HCC in nude mouse models, and may be candidates for the control of recurrence and metastasis after HCC resection.
Insights
Antiangiogenic agents show promise in treating hepatocellular carcinoma (HCC) metastasis. These drugs significantly inhibited tumor growth, angiogenesis, invasion, and metastasis in mouse models, suggesting potential for post-surgery recurrence control.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Hepatocellular carcinoma (HCC) is a prevalent cancer with a high risk of metastasis.
- Metastasis remains a significant challenge in HCC treatment, often leading to recurrence after surgical resection.
- Current therapeutic strategies for metastatic HCC require novel approaches to improve patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of novel antiangiogenic agents in inhibiting tumor growth, angiogenesis, invasion, and metastasis of hepatocellular carcinoma (HCC).
- To assess the potential of these agents as therapeutic strategies for controlling recurrence and metastasis after HCC resection.
Main Methods:
- Utilized the LCI-D20 nude mouse model of metastatic HCC.
- Administered various antiangiogenic agents, including suramin, BB-94 (Batimastat), TNP-470, and carboxyamido-triazole (CAI).
- Monitored and analyzed the inhibitory effects of these agents on tumor growth, angiogenesis, invasion, and metastasis.
Main Results:
- All tested antiangiogenic agents demonstrated significant inhibition of tumor growth in the HCC mouse model.
- Significant suppression of angiogenesis, invasion, and metastasis was observed with the use of these agents.
- The agents effectively reduced the progression of hepatocellular carcinoma in the LCI-D20 model.
Conclusions:
- Antiangiogenic agents are effective in controlling tumor growth, angiogenesis, invasion, and metastasis in experimental HCC models.
- These agents represent promising candidates for the management of recurrence and metastasis following HCC resection.
- Further clinical investigation is warranted to translate these findings into effective treatments for patients with metastatic HCC.
